MedTrace Logo

Vaccine Therapy in Treating Women With Metastatic Breast Cancer

NCT00003638 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 950

Last updated 2013-03-26

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Vaccines may make the body build an immune response to kill tumor cells. It is not yet known whether THERATOPE vaccine therapy is more effective than standard vaccine therapy in treating metastatic breast cancer.

PURPOSE: Randomized double blinded phase III trial to compare the effectiveness of THERATOPE vaccine therapy with that of standard vaccine therapy in treating women who have metastatic breast cancer.

Conditions

Interventions

BIOLOGICAL

Detox-B adjuvant

BIOLOGICAL

THERATOPE STn-KLH vaccine

BIOLOGICAL

keyhole limpet hemocyanin

DRUG

cyclophosphamide

Sponsors & Collaborators

  • Oncothyreon Canada Inc.

    lead INDUSTRY

Principal Investigators

  • BIOMIRA Customer Service (North America) · Oncothyreon Canada Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-01-31
Primary Completion
2007-01-31
Completion
2008-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003638 on ClinicalTrials.gov